DSNK.Y Stock Overview
Manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for DSNK.Y from our risk checks.
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥29.06 |
| 52 Week High | JP¥42.48 |
| 52 Week Low | JP¥26.16 |
| Beta | 0.26 |
| 11 Month Change | -10.69% |
| 3 Month Change | -29.57% |
| 1 Year Change | 7.11% |
| 33 Year Change | 10.92% |
| 5 Year Change | 36.03% |
| Change since IPO | 367.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| DSNK.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.9% | -1.4% | 0.3% |
| 1Y | 7.1% | 10.8% | 31.1% |
Return vs Industry: DSNK.Y underperformed the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: DSNK.Y underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| DSNK.Y volatility | |
|---|---|
| DSNK.Y Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DSNK.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DSNK.Y's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1899 | 18,726 | Sunao Manabe | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent.
Daiichi Sankyo Company, Limited Fundamentals Summary
| DSNK.Y fundamental statistics | |
|---|---|
| Market cap | US$54.85b |
| Earnings (TTM) | US$1.62b |
| Revenue (TTM) | US$11.38b |
33.8x
P/E Ratio4.8x
P/S RatioIs DSNK.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DSNK.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥1.76t |
| Cost of Revenue | JP¥419.99b |
| Gross Profit | JP¥1.34t |
| Other Expenses | JP¥1.09t |
| Earnings | JP¥250.40b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | 132.45 |
| Gross Margin | 76.11% |
| Net Profit Margin | 14.24% |
| Debt/Equity Ratio | 6.3% |
How did DSNK.Y perform over the long term?
See historical performance and comparison